Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA panel sets review date for Thoratec's LVAS (left ventricular assist system):

This article was originally published in Clinica

Executive Summary

An advisory panel to the US FDA is scheduled to review Thoratec's application to expand the intended use of its HeartMate VE LVAS (left ventricular assist system) on March 4. The company's premarket approval supplement, which is based on the results of Thoratec's REMATCH trial (see Clinica, No 985, p 17), is seeking clearance to use the device for long-term support in end-stage heart failure patients who are not eligible for heart transplantation. The device is currently approved for use as a bridge to heart transplant, says the Pleasanton, California firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel